AbbVie Inc (ABBV) Q3 2025 10-Q Quarterly Report
AbbVie Inc (ABBV) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AbbVie Inc Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $15.8B Q3 2025, up 9.1% vs $14.5B Q3 2024; Nine months $44.5B, up 8.0% vs $41.2B prior year
- • Gross margin approx. 66.4% Q3 2025 vs ~70.9% Q3 2024 (calc. from $10.47B/$15.78B vs $10.25B/$14.46B), decline due to $847M intangible impairments
- • Best performing segment: Skyrizi Immunology revenues up 46.8% Q3 and 58.1% YTD; Worst: Humira down 55.4% Q3 and 55.0% YTD from biosimilar competition
- • Operating cash flow $13.8B for nine months, up $2.1B YoY; capital expenditures $885M in 2025 vs $683M prior year; repurchased 3M shares for $606M
- • Management expects regulatory approvals and clinical data readouts; notes pricing pressures from U.S. MFN pricing order and global trade risks; increased dividend 5.5% to $1.73/share starting Q1 2026
Risk Factors
- • Section 'risk_factors' was empty or not found.
AbbVie Inc Q3 2025 Quarterly FinancialsXBRL
Revenue
$15.8B
▲ +9.1% YoY▲ +2.3% QoQ
Net Income
$186M
▼ -88.1% YoY▼ -80.2% QoQ
Operating Margin
12.1%
▼ -1442bp YoY▼ -1966bp QoQ
Net Margin
1.2%
▼ -962bp YoY▼ -490bp QoQ
ROE
-7.0%
Total Assets
$133.9B
EPS (Diluted)
$0.10
▼ -88.6% YoY▼ -80.8% QoQ
Operating Cash Flow
$7.0B
▲ +29.0% YoY▲ +36.3% QoQ
Source: XBRL data from AbbVie Inc Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on AbbVie Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.